SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): November 19, 2003
ARIAD PHARMACEUTICALS, INC.
---------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
-------- ------- ----------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 5. OTHER EVENTS
On November 19, 2003, the Registrant disseminated a Press Release
announcing the first reported high-resolution structure of a
small-molecule drug (its product candidate AP23464) bound to an
important cancer-associated protein (kinase) target known as Src.
The information contained in the Press Release dated November 19,
2003, is incorporated herein by reference and attached as Exhibit
99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated November 19, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: November 19, 2003
2
EXHIBIT INDEX
Exhibit
Number Description Sequential Page Number
- ------- ----------- ----------------------
99.1 The Registrant's Press Release dated November 19, 2003. 4
3